靠抖音撑起“半边天”的西子健康冲刺港交所：99%营收依赖线上，研发投入不足1%

Core Viewpoint - Xizi Health, a sports nutrition food brand heavily reliant on Douyin for its growth, has submitted its listing application to the Hong Kong Stock Exchange, with 99% of its revenue coming from online sales and less than 1% invested in R&D [2][9]. Group 1: Company Overview - Xizi Health primarily offers products such as protein powder, creatine, and functional gummies, with a brand portfolio that includes FoYes, fiboo, Gu Ben Ri Ji, and Hot Rule [2]. - The company has transitioned from a third-party brand operator to a brand owner, achieving significant sales milestones within months of launching its products [4][5]. Group 2: Financial Performance - Revenue from self-owned brands surged from 613 million RMB in 2023 to 1.497 billion RMB in 2024, marking a 144% year-on-year growth, and further increased to 1.566 billion RMB in the first three quarters of 2025, a 38.7% increase from the same period in 2024 [4][5]. - Gross profit margin improved from 44.4% in 2023 to 59.5% in the first three quarters of 2025, with gross profits rising from 642 million RMB in 2023 to 957 million RMB in 2025 [5]. Group 3: Marketing and Sales Strategy - Marketing expenses have risen significantly, accounting for over 40% of total revenue, leading to a decline in net profit margin from 8.9% in 2024 to 7.4% in 2025 [6][8]. - Nearly 99% of Xizi Health's revenue is generated from online direct sales, with Douyin contributing over 60% of this revenue [10][12]. Group 4: Supply Chain and Risks - The company faces supplier concentration risk, relying on a few suppliers for a significant portion of its products, which could adversely affect its supply chain and operations [17].